Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Inotuzumab/bosutinib treat R/R Ph+ ALL, CML in blast phase

Key clinical point: Inotuzumab ozogamicin plus bosutinib may be effective against relapsed/refractory Philadelphia chromosome–positive acute lymphoblastic and chronic myeloid leukemias in blast phase.

Major finding: The median overall survival was 15.4 months.

Study details: Phase 1/2 trial in 18 patients with Ph+ ALL or CML.

Disclosures: Dr. Jain has disclosed consultancy, honoraria, advisory board/committee activity, and research funding from Pfizer, maker of inotuzumab ozogamicin and bosutinib.


Jain N et al. EHA Congress, Abstract EP396.